Pharmacyte Biotech Inc (OTCMKTS:PMCB) revealed that it finalized a contract with Imaging Endpoints in Arizona for completion of radiologic imaging process required to support Phase 2b trial targeting pancreatic cancer. The company stated that it is one of the many announcements that they plan to repot related to Phase IIb study, including a plan of the clinical trial design. The clinical study aims to assess the efficacy of Pharmacyte’s treatment in patients suffering with pancreatic cancer.
The CEO Kenneth L. Waggoner said that they are delighted as Imaging Endpoints accepted to become a part of upcoming clinical trials. The success of this study will be conducive to the overall success of Pharmacyte. Imaging endpoints has an outstanding team and they have expertise in analyzing the radiologic imaging data.
In last trading session, the stock price of Pharmacyte dropped 0.86% to close the trading session at $0.0917.The decline came at a share volume of 1.03 million against monthly average share volume of 1.46 million.
Uluru Inc (OTCMKTS:ULUR) To Raise Funds In Private Placement
Uluru Inc (OTCMKTS:ULUR) reported the signing of a definitive deal to sell nearly 4 million shares of its common stock at a price $0.38 per share to a certain group of European investors. This private placement is expected to generate gross proceeds of $1 million. Under the deal terms, the company is had to submit a registration statement for the registration of the re-sale of the bought shares, and the deal will close after the effectiveness of the filed registration statement.
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) reported that the four proposals highlighted in its yearly meeting proxy statement received the affirmative vote of over a majority of company’s shareholders present at the annual meeting of stockholders. Mr. Russell Harrison and Ms. Sharon Barbari were elected as Oculus class I directors.
On Tuesday, the stock price of Oculus declined more than 2% to close the trading session at $1.15.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: